Besides The Witcher and Cyberpunk, there's a completely new series in development at CD Projekt Red. It's codenamed Hadar and ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Xichem AB (publ), (aXichem), a developer of innovative natural analogue feed additives and dietary supplement ingredients, announces that the company has obtained product registration in Brazil for ph ...

A century after Robert Goddard’s first-ever launch of a liquid-fueled rocket, two NASA experts weigh in on what his legacy ...

Overview Curated list highlights seven impactful books covering fundamentals, tools, machine learning, visualization, and industry.Guides beginners and professi ...

Aible launches SafeClaw that enables long-running agents with built-in enterprise AI governance and guardrails.Aible ...

Analysts say three-screen smartphone successful as a proof of concept, memory crunch potentially made it unsustainable ...

Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase 2 program. Dosing compares two intravitreal dose levels given every 12 or ...

As digital creation continues to evolve, 3D workflows are no longer defined solely by manual modeling or isolated tools.

AI-powered apps are driving higher conversions and revenue, but retention remains weak. High churn, shorter trials, and rising costs expose a gap between early excitement and lasting value.

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...